#None #Class Action #Securities Fraud #Ultragenyx

Ultragenyx Pharmaceutical Inc. Faces Securities Fraud Lawsuit

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has recently found itself at the center of a significant securities fraud class action lawsuit. Investors who purchased common stock of Ultragenyx during the period from August 3, 2023, until December 26, 2025, are urged to take note of this lawsuit, which is currently filed in the United States District Court for the Northern District of California. The case, titled Bailey v. Ultragenyx Pharmaceutical Inc., et al., has a filing deadline for lead plaintiff status set for April 6, 2026.

Allegations in the Lawsuit

The legal complaint outlines several serious allegations against Ultragenyx. It claims that the company, throughout the specified class period, made false and/or misleading statements and failed to disclose crucial information regarding its drug, setrusumab. Specifically, the lawsuit suggests that Ultragenyx gave investors the impression they possessed reliable data on the efficacy of the drug for treating various forms of Osteogenesis Imperfecta, all the while downplaying the inherent risks that patients in their Phase III Orbit study could face.

These allegations also indicate that the company portrayed an overly optimistic view of the Phase III Orbit study's results and the accompanying interim analyses. The complaint argues that Ultragenyx neglected to communicate the risks tied to drawing conclusions based on the Phase II results, which did not include a placebo-controlled group that could provide necessary comparative data. Therefore, it suggests that the reduction in annualized fracture rate (AFR) observed in the Phase II trials might have stemmed from factors like improved standard care or possible placebo effects, rather than the efficacy of setrusumab itself.

Investors are warned that these misrepresentations could significantly mislead them regarding the potential for Ultragenyx's future performance and drug approval processes.

What Affected Investors Can Do

For those who feel they may have been impacted by these developments, several options are available:
1. Lead Plaintiff Status: Investors who wish to take a more active role may file for lead plaintiff status by the Deadline of April 6, 2026. This status allows them to represent the entire class in the litigation process.
2. Consultation with Legal Experts: Kessler Topaz Meltzer & Check, LLP, the law firm handling the lawsuit, offers free case evaluations for affected investors. This could be a valuable opportunity for investors to assess their specific circumstances related to the Ultragenyx stock.
3. Choosing Not to Act: Investors may opt to remain as absent class members without taking any further action. In either case, their ability to recover losses will remain intact, regardless of whether they choose to lead the suit.

Contact Information for Legal Help

For those who experienced financial losses related to Ultragenyx, reaching out to Kessler Topaz Meltzer & Check, LLP is strongly encouraged. Interested individuals may contact attorney Jonathan Naji at (484) 270-1453 or email him at email protected]. For further assistance, investors can visit the firm’s official website at [www.ktmc.com.

Conclusion

As the April 2026 deadline approaches, Ultragenyx Pharmaceutical Inc. investors are encouraged to assess their positions and consider their legal options. This significant lawsuit highlights the importance of transparency and disclosures in corporate communications, particularly when it involves groundbreaking medical developments and investor trust. The outcome could shape not only the future of Ultragenyx but also set a precedent in how companies communicate critical information to their shareholders.